Portuguese integrated CDMO (Loures HQ) with Danish partnership through the Zerion Pharma joint venture on Dispersome drug-delivery technology, plus multi-market active pharmaceutical ingredient supply to Nordic pharma customers.
Hovione is one of Portugal’s largest pharmaceutical companies and a global contract development and manufacturing organisation (CDMO). From its Loures headquarters and its main Portuguese production base in Sete Casas, Hovione delivers active pharmaceutical ingredients (APIs) and drug products to pharma and biotech customers across Europe, including long-standing supply relationships with Nordic-headquartered pharmaceutical companies.
The most visible Nordic anchor is Hovione’s joint venture with Danish drug-delivery specialist Zerion Pharma, which partners Hovione’s manufacturing and particle-engineering platform with Zerion’s Dispersome technology for amorphous solid dispersions — a next-generation approach to solubility enhancement for poorly soluble molecules. The JV combines Danish innovation with Portuguese industrial execution at scale.
Portugal has one of Europe’s strongest pharma manufacturing clusters (Hovione, Bial, Bluepharma, Laboratórios Atral) and Nordic pharma and biotech firms are an increasingly important customer base for the sector. Hovione’s Loures and Sete Casas sites are a reference point for Nordic pharma buyers looking at Portuguese CDMO capacity, and the Zerion JV is one of the highest-profile PT–DK partnerships in life sciences.
Fractio helps Portuguese companies enter the Nordic market — from market sizing to first sales, distribution, and partnerships.
Talk to Fractio →